Medication Adherence Programs in Egypt: What PSPs Actually Deliver

Non-adherence to chronic therapy is not a footnote in a compliance report — it is one of the most consistent drivers of avoidable hospitalization, disease progression, and wasted treatment spend anywhere it has been studied. A patient who quietly stops taking a biologic, skips half their insulin doses, or abandons an oral anticoagulant regimen after the first side effect rarely calls anyone to say so. They simply stop, and the first visible sign is usually a relapse, an ER visit, or a lab result nobody wanted to see.

Studies on chronic therapy adherence have found that a meaningful share of patients on long-term regimens — across cardiovascular disease, diabetes, oncology support therapy, and immunology — do not take their medication as prescribed within the first year, and that this gap widens the longer and more complex the treatment. The exact figures vary by therapeutic area, population, and study design, which is precisely why generic global percentages are of limited use to a pharma brand team trying to plan a launch in Egypt. What matters locally is a different question: given the realities of the Egyptian healthcare system, what actually keeps a patient on therapy, and what does a program built for that purpose measurably achieve?

This piece sets out both halves of that answer — the structural reasons adherence breaks down here, and what a well-run, pharma-sponsored patient support program (PSP) does differently to prevent it, with the verified adherence outcome Hospitalia has achieved across its managed programs.

Why patients in Egypt fall off long-term therapy

The reasons a patient in Cairo or Assiut stops an injectable biologic or a chronic oral regimen are rarely about the drug itself. They are almost always about the logistics and support structure surrounding it, and those logistics look different in Egypt than in the markets most global adherence literature is drawn from.

• Recurring cost of clinic visits: even when the medicine itself is subsidized or supplied through a patient access program, the transport, time off work, and informal clinic fees attached to a monthly injection visit add up and become a reason to skip a dose rather than travel again.
• Distance and governorate coverage gaps: a patient in a satellite city or a rural governorate may be a 90-minute trip from the nearest infusion center capable of administering their therapy, which turns a routine dose into a half-day commitment for the patient and often a family member.
• No structured follow-up between visits: many patients leave a prescribing appointment with a script and no defined touchpoint before the next one, so a missed dose, a side effect, or a storage mistake goes unnoticed until the next scheduled visit — if there is one.
• Low health literacy around side-effect management: patients on injectable or immunosuppressive therapy who experience an unexplained symptom often assume it means the drug is unsafe and quietly discontinue, rather than calling anyone who could explain that the symptom is expected and manageable.
• Extended family caregiving patterns: in many Egyptian households, an elderly or chronically ill patient's adherence depends heavily on whichever family member currently has time to accompany them, which means responsibility for the regimen can shift, and information about it can get lost, every few months.

None of these are reasons a patient is being careless. They are structural gaps — access, distance, information, and continuity — and every one of them is addressable with the right operational design. That is the entire premise of a properly built PSP.

What a structured PSP does differently

A patient support program is not a call center that phones patients to remind them a refill is due. Done properly, it is a set of mechanisms that removes the specific barriers listed above, one at a time, starting from the moment a patient is referred into the program.

• A welcome or referral response within 24 hours of enrollment, so the patient's first experience of the program is immediate and reassuring rather than a delay that lets doubt creep in before treatment has even started.
• Home-based nursing for injections and infusions, which removes the travel barrier entirely for patients who would otherwise need to reach a clinic or hospital every cycle — this is frequently the single change that has the largest effect on whether a patient stays on therapy.
• Scheduled follow-up calls and refill reminders that create a defined touchpoint between visits, so a missed dose or an early side effect is caught within days rather than at the next appointment.
• Bilingual patient and caregiver education — in practice, Arabic-first with English available where needed — covering correct storage, injection or infusion technique, and what side effects are expected versus what warrants an urgent call.
• A named point of contact and escalation path, so the patient and their family know exactly who to call if something feels wrong, instead of defaulting to stopping the medication and waiting to see the prescriber again.

Each of these mechanisms addresses a specific failure mode from the previous section. Home nursing answers distance and cost. Structured follow-up answers the lack of a touchpoint between visits. Bilingual education answers the side-effect literacy gap. None of them is complicated in isolation — the value is in running all of them consistently, for every patient, for the full duration of therapy, which is where informal or ad hoc support arrangements tend to fail.

The adherence numbers

Hospitalia-managed patient support programs have achieved 85% medication adherence among enrolled chronic-therapy patients receiving structured home-based support, including injectable and infusion regimens.

That figure is drawn from programs where every one of the mechanisms above was in place: a welcome contact within 24 hours of referral, home nursing removing the need to travel for administration, scheduled follow-up calls, and bilingual education on technique and side-effect management. It is not a projection or an industry benchmark borrowed from elsewhere — it reflects patients actually enrolled, actually followed up, and actually still on therapy at the point adherence was measured.

What "good" adherence reporting looks like for a pharma partner

A PSP that cannot report on adherence with any granularity is, from a brand team's perspective, indistinguishable from a program that isn't working. The commercial and medical affairs case for running a PSP at all depends on being able to show what happened to the cohort of patients it enrolled, not just how many calls were made.

This is also where thought-leadership content and commercial reality meet: a program that can produce this kind of reporting monthly, without the sponsor having to request it, is the difference between a PSP that supports market access conversations and one that is simply a cost line with no evidence behind it.

Three factors that predict whether a PSP will actually move the adherence needle

Having reviewed and run patient support programs across multiple therapeutic areas in Egypt, three design choices consistently separate programs that move adherence from programs that generate activity without changing outcomes.

1. Home-based, not clinic-based, touchpoints. The single largest predictor of adherence for injectable and infusion therapies in the Egyptian context is whether the patient has to travel to receive the dose. Programs that route patients back to a clinic for administration reintroduce the exact cost and distance barrier the PSP was meant to remove, and adherence curves for those programs tend to look barely different from unsupported patients.
2. Bilingual caregiver education, not just patient education. In a healthcare system where an adult child or spouse frequently manages medication logistics for a parent or partner, a program that only educates the patient and not the caregiver is educating the wrong person half the time. The programs with the strongest adherence outcomes treat the caregiver as a primary audience for training, not an afterthought copied on the call.
3. Structured escalation for missed doses, defined before it is needed. A missed dose is not itself the problem — an unaddressed missed dose is. Programs that have a defined, fast escalation path (who calls the patient back, within what window, and what triggers a call to the prescribing physician) catch and correct non-adherence before it becomes discontinuation. Programs that treat a missed dose as something to note at the next scheduled call routinely lose that patient before the call happens.

None of these three factors is expensive to design for. They are, however, easy to skip when a PSP is assembled quickly or run as a light-touch add-on rather than a properly staffed operation — which is exactly why adherence outcomes vary so widely between programs that look similar on a slide deck.